HealthMyne’s technologies allow physicians to view non-discoverable image evidence through the naked eye and convert it into innovative disease insights.
FREMONT, CA: RefleXion Medical, a clinical oncology organization that is leading biology-guided radiotherapy* (BgRT) as a modern modality for the treatment of all phases of cancer, and HealthMyne, an emerging provider of applied radiotherapy solutions, announced a strategic partnership to bring together the company’s technology to measure and enhance the inherently complex decisions on cancer therapy.
“Our novel BgRT technology produces data-rich CT and PET images at each patient treatment session,” said Thorsten Melcher, Ph.D., Chief Business Officer, RefleXion. “Applying HealthMyne’s unique radiomic insights and AI-enabled algorithms holds the promise of decoding these data so clinicians can use the tumor’s characteristics and its response to radiotherapy to inform and guide the entire patient journey. Instead of delivering standardized treatment protocols, we can now think about the best care plan for each patient and use our biological guidance to deliver it confidently, even one day, to metastatic patients.”
HealthMyne’s technologies allow physicians to view non-discoverable image evidence through the naked eye and convert it into innovative disease insights. The core of HealthMyne’s technologies allows the reliable retrieval of quantitative imaging or structural information, known as radiomic data, to enhance and simplify decision-making in cancer research, screening, treatment preparation, and clinical management. This aspect involves over 1,500 multi-dimensional measurements and novel radiomic data capable of producing statistical algorithms and precision medicine initiatives.
Radiomic data is the basis for imaging biomarkers identified by the Radiological Society of North America as objective tumor characteristics extracted from an image representing normal or disease processes or reaction to a therapeutic intervention. These markers, which offer clinical signatures as specific as any patient, supplement the more commonly recognized genomic or molecular biomarkers. Together, these two independent biomarkers could significantly transform the clinical decision-making environment for cancer treatment.
BgRT uses emissions from cancer cells generated by a patient injecting a small amount of a targeting molecule bearing a positron-emitting radioisotope, known as a PET tracer, to direct external beam radiotherapy. Suppose the tracer binds to the tumor cells. In that case, the emission groups form partial PET images that signal the position of cancer and automatically direct the transmission of a partial dose of radiation. At the end of the therapy session, the entire dosage of radiation is complete, and full CT and PET photographs containing thousands of tumor features are available for radiomic analysis.
“RefleXion’s use of PET emissions to prescriptively determine where to attack the cancer combined with HealthMyne’s ability to objectively measure tumor characteristics and quantify treatment response creates a powerful technological foundation from which to improve patient care,” said Rose Higgins, CEO, HealthMyne. “In the future, clinicians may have the ability to determine much earlier and with a high degree of accuracy, whether changes to the individual patient’s treatment plan are warranted and the predicted outcomes.”